← Therapy pipeline
Investigational · Obesity development

VK2735 injection

VK2735 · Viking Therapeutics

Weekly injectable dual GIP/GLP-1 agonist in global pivotal obesity trials.

GLP-1GIP
Other study areas
Type 2 diabetes
Selected program areas, not approvals. See the full profile for individual trials.
Obesity stagePhase 3Updated as of November 2026
SponsorViking Therapeutics
TargetsGLP-1 + GIP
RouteInjection
DevelopmentObesity-specific
01 / Evidence

Selected study results

VENTURE · injectionMean body-weight reductionBody weight decreased 14.7% · 13 weeks · Phase 2
Phase 2 · Injection · Sponsor-reported numerical results

Mean body-weight reduction · 13 weeks

Study focus: Weight management without type 2 diabetes

Investigational regimen
14.7%
Placebo / comparator
1.7%

Adults with obesity or overweight and a weight-related complication, without diabetes · 15 mg once weekly vs placebo · Trial N=176 · Least-squares means; efficacy population; mixed model. Results & methods ↗

Short dose-finding trial. These are Phase 2 results, not the ongoing VANQUISH Phase 3 outcomes. At 15 mg, 20% discontinued treatment early versus 14% with placebo.

VK2735 maintenance · every other weekProportion of prior weight loss retained at Week 33Prior weight loss retained: 90% · 12 weeks of maintenance · Phase 1
Phase 1 · Injection · Sponsor-reported numerical results

Proportion of prior weight loss retained at Week 33 · 12 weeks of maintenance

Study focus: Weight-loss maintenance

Up to 97% of prior weight loss was retained in an individual every-other-week dose cohort.

Investigational regimen
90%
Placebo / comparator
61%

Adults with obesity after a 21-week VK2735 induction period · 21-week weekly induction, then every-other-week maintenance vs placebo · N not included in this summary · Sponsor topline; combined maintenance regimens. Results & methods ↗

Short Phase 1 maintenance period. The chart shows combined regimen results; dose-cohort maxima are noted separately. These findings do not establish long-term maintenance efficacy.

VK2735 maintenance · monthlyProportion of prior weight loss retained at Week 33Prior weight loss retained: 85% · 12 weeks of maintenance · Phase 1
Phase 1 · Injection · Sponsor-reported numerical results

Proportion of prior weight loss retained at Week 33 · 12 weeks of maintenance

Study focus: Weight-loss maintenance

Up to 90% of prior weight loss was retained in an individual monthly dose cohort.

Investigational regimen
85%
Placebo / comparator
61%

Adults with obesity after a 21-week VK2735 induction period · 21-week weekly induction, then monthly maintenance vs placebo · N not included in this summary · Sponsor topline; combined maintenance regimens. Results & methods ↗

Short Phase 1 maintenance period. The chart shows combined regimen results; dose-cohort maxima are noted separately. These findings do not establish long-term maintenance efficacy.

Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.

02 / How it works

Mechanism at a glance

GLP-1GLP-1Targeted
GIPGIPTargeted
GCGglucagon—
AMYamylin—
OTHOther targets—
Explore the hormone anatomy ↗
03 / Development

Obesity stage by formulation

InjectionOnce weekly
Phase 3VANQUISH Phase 3 active
Milestone → next

Latest: VANQUISH-1 and VANQUISH-2 Phase 3 obesity trials are fully enrolled. Part 2 of the separate exploratory maintenance study began in October 2026; Viking corrected its dosing description on October 14.

Next: VANQUISH Phase 3 outcomes. Maintenance Part 2 tests daily oral, monthly subcutaneous, or every-other-week subcutaneous dosing after 21 weeks of weekly injections; results are expected in 2027. This exploratory study is separate from the Phase 3 registration program.

04 / Study records

Clinical study records

Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.

Obesity and weight-management studies

Phase 3 studies2 records

Phase 3

VANQUISH-1

Weight management
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Adults with obesity or overweight and a weight-related comorbidity, without type 2 diabetes.

Phase 3

VANQUISH-2

Weight management with type 2 diabetes
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Adults with obesity or overweight and type 2 diabetes.

Phase 2 studies1 record